Home Cart Sign in  
Chemical Structure| 82373-94-2 Chemical Structure| 82373-94-2

Structure of 82373-94-2

Chemical Structure| 82373-94-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

2,3,4',5-Tetrahydroxystilbene 2-O-Glucoside inhibits the formation of 5-HETE, HHT and thromboxane B2, it is a natural product isolated and purified from the roots of Polygonum species.

Synonyms: TSG; trans-2,3,5,4′-Tetrahydroxystilbene-2-O-β-d-Glucopyranoside; (E )-2,3,5,4′-Tetrahydroxystilbene-2-O-Glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside

CAS No. :82373-94-2
Formula : C20H22O9
M.W : 406.38
SMILES Code : OC1=C(C(/C=C/C2=CC=C(C=C2)O)=CC(O)=C1)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO
Synonyms :
TSG; trans-2,3,5,4′-Tetrahydroxystilbene-2-O-β-d-Glucopyranoside; (E )-2,3,5,4′-Tetrahydroxystilbene-2-O-Glucoside
MDL No. :MFCD00238694
InChI Key :JAYVHSBYKLLDJC-DSNJPTTOSA-N
Pubchem ID :5321884

Safety of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
IMR-90 fibroblasts 10 and 100 μM 48 h To investigate the effects of TSG on AMPK and Tet2 expression in senescent fibroblasts. Results showed that TSG treatment significantly increased phosphorylation levels of AMPK T172 and acetyl-CoA carboxylase (ACC), which was markedly inhibited by co-treatment with AMPK inhibitor Compound C. PMC11976424
Primary microglia 50 μM 30 min TSG reduced iNOS expression and NO production in LPS-stimulated primary microglia. PMC3854509
Primary microglia 50 μM 30 min TSG reduced the iNOS expression and NO production in LPS-stimulated primary microglia. PMC3854509
BV-2 cells 50 μM 30 min TSG significantly reduced the increase in iNOS expression in LPS-stimulated BV-2 cells and decreased the production of NO, TNF-α, and IL-6. PMC3854509
H9c2 cardiomyoblasts 1, 10, 100 μM 8 h To evaluate the protective effect of TSG against simulated ischemia/reperfusion (SIR) injury. Results showed that TSG pretreatment significantly increased cell viability and reduced SIR-induced apoptosis. PMC5342668
H9c2 cardiomyoblasts 0.1, 1, 10, 100, 1000 μM 8 h To evaluate the effect of TSG on the survival of H9c2 cardiomyoblasts. Results showed that TSG at concentrations from 0.1 to 1000 μM did not significantly affect cell viability. PMC5342668
neonate rat cardiomyocytes 10−300 μM 24 h THSG ameliorated DOX-induced cardiomyocyte apoptosis in a concentration-dependent manner, inhibited ROS generation, prevented loss of mitochondrial membrane potential, inhibited caspase-3 activation and upregulation of Bax protein expression, and increased Bcl-2 protein level. PMC4003005
PC12 neuronal-like cells 0.4-2.0 μg/mL 24 h EH-201 induced PGC-1α and hemoglobin expression via EPO-mediated signaling, enhanced mitochondrial activity, and reduced oxidative stress. PMC4594276
astrocytes 0.4-2.0 μg/mL 24 h EH-201 induced PGC-1α and hemoglobin expression via EPO-mediated signaling, enhanced mitochondrial activity, and reduced oxidative stress. PMC4594276
CL4176 worms 100, 200, and 400µM from L1 stage Significantly delayed paralysis by approximately 35.57% in CL4176 worms expressing human A β in body wall muscle. PMC11428426
Caenorhabditis elegans N2 100, 200, and 400µM from L4 stage Significantly extended the mean lifespan of N2 worms by 16.48% and improved health status by delaying age-associated physiological decline. PMC11428426
mouse cochlear cell line UB/OC-2 5, 10, 20 µM 6 h To evaluate the protective effect of THSG against gentamicin-induced ototoxicity. Results showed that THSG significantly attenuated gentamicin-induced cytotoxicity, reduced LDH release, and decreased the expression of autophagy-related proteins. PMC8989425
mouse cochlear UB/OC-2 cells 5-40 μM 6-48 h THSG protects cells from oxidative stress damage by activating the Nrf2 antioxidant pathway and reducing H2O2-induced autophagy and apoptosis. PMC7175305

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Total body irradiation (TBI)-induced premature aging model and naturally aged mice model Oral gavage 120 mg/kg Once daily for 60 days To evaluate the rejuvenation effects of TSG on aging hematopoietic stem cells (HSCs). Results demonstrated that TSG treatment significantly increased the absolute numbers of common lymphoid progenitors (CLPs) and B lymphocytes, and improved the repopulation capacity of HSCs, which were dependent on the activation of AMPK-Tet2 axis. PMC11976424
C57Bl/6 mice Myocardial ischemia/reperfusion (MI/R) injury model Oral gavage 60 mg/kg Once daily for 2 weeks To evaluate the protective effect of TSG against MI/R injury. Results showed that TSG pretreatment significantly improved post-operative cardiac function, reduced myocardial apoptotic index, and decreased serum levels of LDH and CK. PMC5342668
Kunming male mice Acute mouse model of DOX-induced cardiotoxicity Intraperitoneal injection 0.1 g/kg 2 days before and 5 days after DOX injection THSG significantly reduced DOX-induced cardiotoxicity, including animal mortality, histopathological changes, and levels of serum creatine kinase (CK) and lactate dehydrogenase (LDH). Moreover, THSG was able to attenuate the increased malondialdehyde (MDA) and decreased reduced glutathione (GSH) caused by DOX. PMC4003005
C57BL/6J mice Sleep-deprived model, Aβ25-35-injected model, and kainic acid-injected model Oral 50, 100, or 200 mg/kg Once daily for 3 days to 2 weeks EH-201 restored memory impairment by inducing endogenous EPO expression and increased levels of EPO, PGC-1α, and hemoglobin in the hippocampus. PMC4594276
Caenorhabditis elegans N2 wild-type C. elegans Liquid medium 200 µM From L4 stage until death Extended lifespan and improved health status by delaying age-associated physiological decline. PMC11428426

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.61mL

4.92mL

2.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories